RTP Mobile Logo
Novel Agents and Emerging Strategies in the Management of Metastatic Colorectal Cancer — Video Program
Released January 2016

Featuring perspectives from Drs John L Marshall and Eric Van Cutsem. (Video Program)

CE Disclosures and Faculty Information

  • TARGET AUDIENCE
    This activity is intended for medical oncologists and other healthcare providers involved in the treatment of colorectal cancer (CRC).

    OVERVIEW OF ACTIVITY
    Metastatic CRC (mCRC) is a common and often lethal condition, and its clinical management is constantly evolving. As published results from ongoing trials lead to the emergence of novel biomarkers and new therapeutic targets and regimens, existing treatment algorithms may be altered. In order to offer optimal patient care — including the option of clinical trial participation — the practicing medical oncologist must be well informed of these advances. To bridge the gap between research and patient care, this special edition interview program uses one-on-one discussion with 2 leading gastrointestinal oncology investigators. By providing access to the latest scientific developments and the perspectives of experts in the field, this CME activity assists medical oncologists with the formulation of up-to-date management strategies.

    LEARNING OBJECTIVES

    • Coordinate comprehensive biomarker analysis for patients diagnosed with mCRC, and use this information to guide evidence-based care for these patients.
    • Communicate the benefits and risks of approved anti-VEGF, anti-EGFR and other targeted biologic therapies to patients with mCRC, and develop an evidence-based algorithm to sequence available options based on disease- and patient-specific characteristics.
    • Understand practical considerations surrounding the use of regorafenib for patients with mCRC to ensure appropriate administration and patient safety.
    • Assess the potential role of anti-PD-1 antibodies in the treatment of mCRC.
    • Counsel appropriately selected patients with mCRC about participation in ongoing clinical trials.

    ACCREDITATION STATEMENT
    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CME credit is no longer available for this issue

    CREDIT DESIGNATION STATEMENT

    CME credit is no longer available for this issue

    CREDIT FOR INTERNATIONAL CLINICIANS

    CME credit is no longer available for this issue

    HOW TO USE THIS CME ACTIVITY
    This CME activity consists of a video component.

    CME credit is no longer available for this issue

    CONTENT VALIDATION AND DISCLOSURES
    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

    John L Marshall, MD
    Chief, Hematology and Oncology
    Director, Ruesch Center for the Cure of GI Cancers
    Lombardi Comprehensive Cancer Center
    Georgetown University
    Washington, DC

    Advisory Committee: Amgen Inc, Bayer HealthCare Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals Inc, Celgene Corporation, Daiichi Sankyo Inc, Genentech BioOncology; Consulting Agreements, Contracted Research and Speakers Bureau: Amgen Inc, Bayer HealthCare Pharmaceuticals, Celgene Corporation, Genentech BioOncology.

    Eric Van Cutsem, MD, PhD
    Professor of Medicine
    Digestive Oncology
    University Hospital Gasthuisberg/Leuven
    Leuven, Belgium

    Consulting Agreements: Bayer HealthCare Pharmaceuticals, Lilly; Research Grants: Amgen Inc, Bayer HealthCare Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals Inc, Merck Serono, Novartis Pharmaceuticals Corporation, Roche Laboratories Inc, Sanofi.

    EDITOR — Dr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Amgen Inc, Astellas Pharma Global Development Inc, AstraZeneca Pharmaceuticals LP, Baxalta Inc, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Pharma Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, CTI BioPharma, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, Exelixis Inc, Foundation Medicine, Genentech BioOncology, Genomic Health Inc, Gilead Sciences Inc, ImmunoGen Inc, Incyte Corporation, Janssen Biotech Inc, Jazz Pharmaceuticals Inc, Lilly, Medivation Inc, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, NanoString Technologies, Natera Inc, Novartis Pharmaceuticals Corporation, Novocure, Onyx Pharmaceuticals, an Amgen subsidiary, Pharmacyclics Inc, Prometheus Laboratories Inc, Regeneron Pharmaceuticals, Sanofi, Seattle Genetics, Sigma-Tau Pharmaceuticals Inc, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Teva Oncology, Tokai Pharmaceuticals Inc and VisionGate Inc. 

    RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This activity is supported by educational grants from Bayer HealthCare Pharmaceuticals and Lilly.

    Hardware/Software Requirements:
    A high-speed Internet connection
    A monitor set to 1280 x 1024 pixels or more
    Internet Explorer 7 or later, Firefox 3.0 or later, Chrome, Safari 3.0 or later
    Adobe Flash Player 10.2 plug-in or later
    Adobe Acrobat Reader
    (Optional) Sound card and speakers for audio

    Last review date: January 2016
    Expiration date: January 2017


    After completing the Post-test, learners may download and review the answers here in order to identify further areas of study.

Acknowledge and close

Watch video
(WIFI is recommended for best performance):


Emerging treatment paradigms in mCRC
Anti-PD-1 antibodies in MSI-high mCRC
Caring for patients with BRAF V600E mutation-positive disease
HERACLES: A Phase II trial of trastuzumab and lapatinib in HER2-amplified mCRC

First- and second-line treatment of mCRC
First-line treatment of KRAS/RAF wild-type metastatic disease
Second-line treatment in patients receiving first-line oxaliplatin/capecitabine/bevacizumab
Choice of biologic: Continuation of bevacizumab versus aflibercept versus ramucirumab
Case: A patient with fluoropyrimidine-related coronary vasospasm

Regorafenib in advanced mCRC
Case presentation: A 50-year-old man with multiple prior treatments for metastatic disease
Dosing of regorafenib
Time course of regorafenib toxicity
Central tumor necrosis and treatment benefits of regorafenib

Newest approved therapy for mCRC: TAS-102
Clinical profile of TAS-102
Sequencing of TAS-102 and regorafenib